Drugs / ODM-203
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03240445 | Aug → Oct 2017 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02264418 | Sep 2014 → May 2019 | cancer | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-203 | “Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours” NCT02264418 ↗ |
| Action | Inhibit | “FGFR and VEGFR inhibitor” PMID 33262202 ↗ Dec 2020 |
| Route | Oral | “Oral capsules given once daily dosage 50-800mg” NCT02264418 ↗ |